| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2008PLoSO...3.2445C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0002445 |
| P932 | PMC publication ID | 2409077 |
| P698 | PubMed publication ID | 18560576 |
| P5875 | ResearchGate publication ID | 5295304 |
| P50 | author | Wen Zhou | Q56811723 |
| Wei-Guo Zhu | Q42962893 | ||
| P2093 | author name string | Yang Yang | |
| Yu Yu | |||
| Lian Li | |||
| Ying Zhao | |||
| Gregory A Otterson | |||
| Xin Wu | |||
| Haiying Wang | |||
| Michael A McNutt | |||
| Lipeng Wu | |||
| Yingqi Chen | |||
| Shaoli Lu | |||
| Donglai Wang | |||
| Ye-Guang Hu | |||
| Guolin Chai | |||
| P2860 | cites work | DNA methylation patterns and epigenetic memory | Q22065780 |
| Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals | Q22122053 | ||
| Instability and decay of the primary structure of DNA | Q22122361 | ||
| Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex | Q24324026 | ||
| Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin | Q24672721 | ||
| Worms gang up on bacteria | Q27860588 | ||
| An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication | Q28204037 | ||
| Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints | Q28266170 | ||
| Novel activities of human uracil DNA N-glycosylase for cytosine-derived products of oxidative DNA damage | Q28610607 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Cancer epigenomics: DNA methylomes and histone-modification maps | Q29615524 | ||
| Methyl CpG binding proteins: coupling chromatin architecture to gene regulation | Q30654814 | ||
| Inactivation of the apoptosis effector Apaf-1 in malignant melanoma | Q31984891 | ||
| Uracil-DNA glycosylase (UNG)-deficient mice reveal a primary role of the enzyme during DNA replication | Q33911300 | ||
| Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors | Q33926864 | ||
| Recombinational repair and restart of damaged replication forks. | Q33962242 | ||
| Incorporation and excision of 5-fluorouracil from deoxyribonucleic acid in Escherichia coli | Q34116328 | ||
| Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. | Q34225624 | ||
| Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint | Q46058691 | ||
| The fundamental role of epigenetic events in cancer | Q56421597 | ||
| Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate | Q71726732 | ||
| Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine | Q72310743 | ||
| Mechanism for exclusion of 5-fluorouracil from DNA | Q72419830 | ||
| Comet assay and early apoptosis | Q74019471 | ||
| Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). | Q34520098 | ||
| Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter | Q35019557 | ||
| Who's on first in the cellular response to DNA damage? | Q35120155 | ||
| ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. | Q35200276 | ||
| Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts | Q35206290 | ||
| Epigenetic targets in hematopoietic malignancies | Q35551110 | ||
| Pathways for mitotic homologous recombination in mammalian cells | Q35595530 | ||
| Mechanisms of apoptosis induction by nucleoside analogs. | Q35603389 | ||
| Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation | Q35939534 | ||
| Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase | Q36145017 | ||
| Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid | Q36303956 | ||
| Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control | Q36490482 | ||
| De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase | Q36561731 | ||
| The ATR pathway: fine-tuning the fork | Q36832714 | ||
| Epigenetics and aging: the targets and the marks | Q36845462 | ||
| Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity | Q37282145 | ||
| An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment | Q38296791 | ||
| Activation of DNA-dependent protein kinase by single-stranded DNA ends | Q38316514 | ||
| Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice | Q39453459 | ||
| 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). | Q40215916 | ||
| Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells | Q40265938 | ||
| Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. | Q40453329 | ||
| Preferential response of cancer cells to zebularine. | Q40523300 | ||
| 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells | Q40531794 | ||
| Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine | Q40599549 | ||
| 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. | Q40599594 | ||
| Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells | Q40618910 | ||
| Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells | Q41070371 | ||
| DNA alkali-labile sites induced by incorporation of 5-aza-2'-deoxycytidine into DNA of mouse leukemia L1210 cells | Q41242502 | ||
| Increased levels of 5-fluorouracil-induced DNA lesions in Bloom's syndrome | Q41740521 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| New substrates for old enzymes. 5-Hydroxy-2'-deoxycytidine and 5-hydroxy-2'-deoxyuridine are substrates for Escherichia coli endonuclease III and formamidopyrimidine DNA N-glycosylase, while 5-hydroxy-2'-deoxyuridine is a substrate for uracil DNA N- | Q42283571 | ||
| 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation | Q42390503 | ||
| Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. | Q43540223 | ||
| DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. | Q43540230 | ||
| Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. | Q43548377 | ||
| Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. | Q43551866 | ||
| Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer | Q43761430 | ||
| Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage | Q43829332 | ||
| Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells | Q43831000 | ||
| Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody | Q44140576 | ||
| Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. | Q44183128 | ||
| The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. | Q44826959 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | e2445 | |
| P577 | publication date | 2008-06-18 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells | |
| P478 | volume | 3 |
| Q34428877 | 5-aza-2'-deoxycytidine leads to reduced embryo implantation and reduced expression of DNA methyltransferases and essential endometrial genes |
| Q33417499 | A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. |
| Q33431457 | A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients |
| Q39851827 | Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines |
| Q37645183 | Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines |
| Q38630705 | BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma |
| Q34405013 | Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation |
| Q39672023 | Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression |
| Q90431602 | Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells |
| Q34320121 | DNA and histone deacetylases as targets for neuroblastoma treatment |
| Q39620587 | Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. |
| Q53098086 | Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. |
| Q37620142 | Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses |
| Q38696932 | Histone Deacetylase Inhibitors as Anticancer Drugs |
| Q36049516 | Histone deacetylase modulators provided by Mother Nature |
| Q39152245 | Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines |
| Q28474843 | Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications |
| Q46074208 | Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. |
| Q38738800 | Physcion 8-O-β-glucopyranoside induces apoptosis, suppresses invasion and inhibits epithelial to mesenchymal transition of hepatocellular carcinoma HepG2 cells |
| Q38739076 | Physcion 8-O-β-glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1. |
| Q40305547 | Physcion induces apoptosis in hepatocellular carcinoma by modulating miR-370. |
| Q33408509 | Romidepsin for the treatment of T-cell lymphomas |
| Q39011822 | SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome |
| Q38881033 | Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine |
| Q39529163 | TGF-β1, EGF and FGF4 synergistically induce differentiation of the seminoma cell line TCam-2 into a cell type resembling mixed non-seminoma. |
| Q38002967 | Targeting epigenetic mediators of gene expression in thoracic malignancies. |
| Q26853394 | Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications |
| Q38821103 | Targeting the cancer epigenome for therapy |
| Q24609974 | Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy |
| Q37408820 | The comet assay: a sensitive method for detecting DNA damage in individual cells |
| Q39460297 | The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression |
| Q37902054 | Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. |
| Q53651729 | Ursolic acid inhibited growth of hepatocellular carcinoma HepG2 cells through AMPKα-mediated reduction of DNA methyltransferase 1. |
| Q38016227 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results |
| Q35206525 | β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1. |
Search more.